[Breaking] Sinsungdeltatech Surges 21% in Regular Session, Hits Upper Limit in NXT After-Hours
Sinsungdeltatech (065350), following a surge of more than 20% in the Korea Exchange (KRX) regular session on the 29th, continued to attract strong buying pressu
![[Breaking] Sinsungdeltatech Surges 21% in Regular Session, Hits Upper Limit in NXT After-Hours](https://media.cbcglobe.com/tenants/cbc00000-0000-4000-8000-000000000001/media/cbc/2026/06/581031/0c2a8f5a6d5bef88/variants/hero.webp)
Sinsungdeltatech (065350), following a surge of more than 20% in the Korea Exchange (KRX) regular session on the 29th, continued to attract strong buying pressure in the after-hours Nextrade (NXT) market, reaching the upper limit.
On this day, Sinsungdeltatech closed in the regular market at 34,000 won, up 5,900 won (21.00%) from the previous trading day. The upward momentum continued even after the regular session closed.
As of 5:38 p.m., the stock soared to 36,500 won in the NXT after-hours market. This represents an increase of 8,400 won (29.89%) from the previous trading day, reaching the price limit, and is approximately 2,500 won higher than the regular session closing price.
With massive buying pressure flowing into after-hours trading following the regular session, the stock's gain expanded further. However, market attention is focused on whether the current surge will continue into the next trading day's regular session.
Meanwhile, the KOSDAQ index, which includes Sinsungdeltatech, also surged more than 8% to close at 920.57.
[This article is not intended to solicit investment. Investment decisions and final responsibility rest with the investor.]
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.
![[Breaking] Doosan Enerbility VI Triggered... Surges 9% After Two-Day Correction, Reclaiming 88,000 Won Level](https://media.cbcglobe.com/tenants/cbc00000-0000-4000-8000-000000000001/media/cbc/2026/06/580163/1396d4e6f2ae151a/variants/hero.webp)
![[Breaking News] Samsung Bioepis' Keytruda Biosimilar 'SB27' Demonstrates Equivalence in Global Phase 3 Trial](https://media.cbcglobe.com/tenants/cbc00000-0000-4000-8000-000000000001/media/cbc/2026/06/579545/36de0fb87055dd02/variants/hero.webp)
![[Breaking] C&G Hi-Tech Signs 20.3 Billion Won Semiconductor Manufacturing Equipment Supply Contract with Samsung Electronics, Nearing 10% of Annual Revenue](https://media.cbcglobe.com/tenants/cbc00000-0000-4000-8000-000000000001/media/cbc/2026/06/581911/a630da1c47d6049c/variants/hero.webp)
